Photo by naomish from unsplash
Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first-line drug for axSpA patients. Failed to NSAIDs therapy, tumor necrosis factor (TNF)-a inhibitor (TNFi) was suggested in the treatment strategy of… Click to show full abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first-line drug for axSpA patients. Failed to NSAIDs therapy, tumor necrosis factor (TNF)-a inhibitor (TNFi) was suggested in the treatment strategy of axSpA. But 30% of axSpA patients still do not respond or respond inadequately to the TNFi therapy. Moreover, TNF-a antagonists are believed to have a weak effect on preventing osteophyte formation and spinal structure damage in axSpA.
Keywords:
real life;
axial spondyloarthritis;
life effectiveness;
safety secukinumab;
secukinumab axial;
effectiveness safety
Journal Title: Chinese Medical Journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Chinese Medical Journal
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!